Aflibercept for Relapsed Multiple Myeloma

Summary

This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment. Aflibercept may be able to carry cancer-killing substances directly to multiple myeloma cells. It may also stop the growth of multiple myeloma by blocking blood flow to the cancer.

Timeline

Start

2007-01

Primary completion

2010-10

Completion

2011-04

Drugs

Indications